Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for Comprar returned no results
Showing 31 to 45 of 557 results for compare

  1. Percutaneous radiofrequency ablation for renal cancer (HTG226)

    Evidence-based recommendations on percutaneous radiofrequency ablation of renal cancer. This involves using heat produced through electrodes placed into the tumour to destroy the cancer cells.

    HealthTech guidance
    Published
    28 July 2010
    View recommendations

    Sections for HTG226

  2. Urinary incontinence and pelvic organ prolapse in women. Patient decision aid on surgery for uterine prolapse

    type of treatment: what it involves, the risks and benefits, and how they compare to each other. To help you understand the...

  3. Tivozanib for treating advanced renal cell carcinoma (TA512)

    Evidence-based recommendations on tivozanib (Fotivda) for treating advanced renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    21 March 2018
    View recommendations

    Sections for TA512

  4. How effective and cost effective are different types of exercise referral scheme? Compare the relative effects of different models in controlled studies. Include health-related quality of life as an outcome. Compare exercise referral schemes that vary by: - setting – for example, home-based, gym-based, community-based or outdoors - intensity and duration – for example, a 12-week scheme involving 1 session a week, or a 6-week scheme involving 4 1-hour sessions per week - the techniques used, for example, some use additional 'supportive' techniques such as 'motivational interviewing' and education sessions - the target group, for example, people who are overweight and obese, people with raised blood pressure or cholesterol levels or those experiencing mild depression, anxiety or stress; or by age, gender, race or socioeconomic status - other scheme characteristics including: design, content and delivery; referral mechanisms; choice of activity; cost and qualifications of instructors; and whether it is commissioned and delivered by an NHS, non-NHS or community-based organisation.

    scheme? Compare the relative effects of different models in controlled studies. Include health-related quality of life as an outcome....

    Research recommendation
    Published
    9 June 2015

  5. Long-term complications of spondyloarthritis:- What is the incidence of long-term complications, in particular osteoporosis, cardiovascular disease (CVD) and metabolic syndrome, in people with spondyloarthritis, and how does this compare with the general population? Are any specific spondyloarthritis features or risk factors associated with the incidence and outcomes of these complications?

    metabolic syndrome, in people with spondyloarthritis, and how does this compare with the general population? Are any specific...

    Research recommendation
    Published
    4 May 2017

  6. Percutaneous cryotherapy for renal cancer (HTG269)

    Evidence-based recommendations on percutaneous cryotherapy for renal tumours. This involves inserting instruments that apply cold temperatures into the tumour to destroy the cancer cells.

    HealthTech guidance
    Published
    27 July 2011
    View recommendations

    Sections for HTG269

  7. Urinary incontinence and pelvic organ prolapse in women. Patient decision aid on surgery for stress urinary incontinence

    type of treatment: what it involves, the risks and benefits, and how they compare to each other. To help you understand the...

  8. Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (TA787)

    Evidence-based recommendations on venetoclax (Venclyxto) with low dose cytarabine for untreated acute myeloid leukaemia in adults when intensive chemotherapy is unsuitable.

    Technology appraisal guidance
    Published
    27 April 2022
    View recommendations

    Sections for TA787

  9. Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia (TA1013)

    Evidence-based recommendations on quizartinib (Vanflyta) for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia in adults.

    Technology appraisal guidance
    Published
    23 October 2024
    View recommendations

    Sections for TA1013

  10. Ceritinib for untreated ALK-positive non-small-cell lung cancer (TA500)

    Evidence-based recommendations on ceritinib (Zykadia) for untreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    24 January 2018
    View recommendations

    Sections for TA500

  11. Upadacitinib for treating severe rheumatoid arthritis (TA665)

    Evidence-based recommendations on upadacitinib (Rinvoq) for severe active rheumatoid arthritis in adults.

    Technology appraisal guidance
    Published
    9 December 2020
    View recommendations

    Sections for TA665

  12. Radiofrequency ablation for symptomatic interdigital (Morton's) neuroma (HTG394)

    Evidence-based recommendations on radiofrequency ablation for symptomatic interdigital (Morton’s) neuroma. This involves using pulses of radiofrequency heat energy to damage the nerve, with the aim of reducing pain.

    HealthTech guidance
    Published
    16 December 2015
    View recommendations

    Sections for HTG394

  13. Idelalisib for treating refractory follicular lymphoma (TA604)

    Evidence-based recommendations on idelalisib (Zydelig) for follicular lymphoma that has not responded to 2 prior lines of treatment in adults.

    Technology appraisal guidance
    Published
    2 October 2019
    View recommendations

    Sections for TA604

  14. Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders (TA748)

    Evidence-based recommendations on mexiletine (Namuscla) for treating the symptoms of myotonia in adults with non-dystrophic myotonic disorders.

    Technology appraisal guidance
    Published
    1 December 2021
    View recommendations

    Sections for TA748

  15. Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over (TA1039)

    Evidence-based recommendations on selpercatinib (Retsevmo) for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over.

    Technology appraisal guidance
    Published
    12 February 2025
    View recommendations

    Sections for TA1039